Gut barrier and microbiota changes with glycine and branched-chain amino acid supplementation in chronic haemodialysis patients.
慢性血液透析患者におけるグリシンおよび分岐鎖アミノ酸補給による腸管バリアとマイクロバイオータの変化 (機械翻訳の邦題)
記録の確認項目
- 研究デザイン
- ランダム化比較試験
- 対象
- ヒト
- 出版年
- 2021
- 出典
- doi.org
- 抄録の表示
- 表示あり
- 出版状態
- 有効な記録
- 状態確認日
- 2026/08/17
- 収集日
- 2026/08/03
- 鮮度
- 確認期限内
- 確認段階
- 自動処理
- 記録状態
- 公開
日本語要約(機械生成)
慢性血液透析患者を対象に、グリシンと分岐鎖アミノ酸(BCAA)の補給が腸管バリアとマイクロバイオータに及ぼす影響を評価した多施設無作為化二重盲検クロスオーバー試験。栄養不良の特徴を有する患者27名を解析し、各補給前後で糞便マイクロバイオータ、IgA、血清サイトカイン、腸管透過性マーカー、食欲関連メディエーター、エンドカンナビノイドを測定した。その結果、補給の種類による有意な影響は認められず、マイクロバイオータの組成や多様性も変化しなかった。ただし、BCAA補給によりLacticaseibacillus paracaseiとBifidobacterium dentiumの存在比が有意に減少した。
この要約は公開抄録のみを根拠にAIが機械的に生成したものです。正確な内容は原文を確認してください。
抄録
Background: We have previously shown that glycine increases fat-free mass in chronic haemodialysis patients with features of malnutrition as compared with branched-chain amino acids (BCAAs). This multicentre randomized double-blind crossover study evaluates the impact of these amino acids on the gut barrier and microbiota.Methods: Haemodialysis patients were included if they had plasma albumin <38 g/L or weight loss >5% of dry body weight, and daily dietary intakes <30 kcal/kg and <1 g protein/kg. They consumed glycine or BCAA (7 g twice daily) for 4 months and underwent a 1 month washout period, before crossover of supplementations. Faecal microbiota (16S rRNA gene sequencing) and immunoglobulin A (IgA), serum levels of cytokines, surrogate markers of intestinal permeability, appetite mediators, and endocannabinoids were obtained at the start and end of each supplementation. Supplementations were compared by multiple mixed linear regression models, adjusted for age, sex, month of supplementation (0 and 4 in each period), and period (Period 1: first 4 months; Period 2: last 4 months). Microbiota comparisons were performed using principal coordinate analysis and permutational multivariate analysis of variance, Shannon diversity index estimate and analysis of composition of microbiomes analysis, and Wilcoxon tests.Results: We analysed 27 patients compliant to the supplementations. Multiple mixed linear regression models were significant only for interleukin-6 (P = 0.002), glucagon-like peptide 1 (P = 0.028), cholecystokinin (P = 0.021), and peptide YY (P = 0.002), but not for the other outcomes. The significant models did not show any impact of the type of supplementation (P < 0.05 in all models). Principal coordinate analysis and permutational multivariate analysis of variance (P = 0.0001) showed strong microbiota clustering by subject, but no effect of the amino acids. Bacterial alpha diversity and zero-radius operational taxonomic unit richness remained stable, whatever the supplementation. Lacticaseibacillus paracasei (0.030; Q1-Q3 0.008-0.078 vs. 0.004; Q1-Q3 0.001-0.070) and Bifidobacterium dentium (0.0247; Q1-Q3 0.002-0.191 vs. 0.003; Q1-Q3 0.001-0.086) significantly decreased with the BCAA supplementation.Conclusions: The BCAA and glycine supplementations had no impact on the serum levels of cytokines, appetite mediators, intestinal permeability, endocannabinoids, or faecal IgA. Overall faecal microbiota composition and microbial diversity did not change with the glycine or BCAA supplementation but decreased the abundance of L. paracasei and B. dentium.
MeSH
DOI 10.1002/jcsm.12781
PMID 34535959
原文・出典を見る →